Mercer International Stock Surges 45% on C$20 Million Canada Funding 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
GM Plans C$1.1 Billion Canada Investment Amid U.S. Tariff Pressure 
Finland’s Stubb Says Russia Unlikely to Attack NATO 
Meta Agrees to $18 Billion Settlement, Tightens Teen Social Media Rules 
Canada Backs €100B Global Defence Bank as G7 Support Lags 
U.S. Strikes Iranian Launchers on Larak Island 
Nvidia Pauses AI Cloud Financing Deals Amid Antitrust Concerns 
Norway’s King Harald Dies at 89, Haakon VIII Takes Throne 
Street Poller Media and The Boom of the Street Interview Ad Industry 
Top US General Says No Troops Planned at Polling Places 
Brazil, US Resume Tariff Talks as Trade Tensions Persist 
Shein Hong Kong IPO to Raise $1.7 Billion at $26.5 Billion Valuation 
Nepal Seeks More China Glacier Data After Deadly Himalayan Flood 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
Add as a preferred source on Google
President Donald Trump announced new drug pricing agreements with nine pharmaceutical companies on Monday, expanding his administration’s campaign to lower prescription drug costs for Americans.
The agreements involve Astellas, BeOne Medicines, CSL, BridgeBIO, Sun Pharmaceutical, Teva and UCB SA, among other participating drugmakers. Under the deals, the companies will provide medicines to state Medicaid programs at most-favored-nation prices, tying costs more closely to lower prices available in other developed countries.
Speaking during an Oval Office event alongside pharmaceutical executives, Trump said the agreements would deliver significant discounts and help reduce healthcare expenses for patients across the United States.
Prescription drug prices in the U.S. remain among the highest in the developed world. Americans can pay nearly three times as much for certain medicines as patients in other wealthy countries. The Trump administration has increasingly pressured pharmaceutical companies to narrow that gap by adopting international reference pricing.
The latest agreements build on deals reached with 17 major pharmaceutical companies beginning last year. Pfizer, Eli Lilly and Amgen were among the companies that previously agreed to lower prices on selected medicines for federal healthcare programs.
Some participating drugmakers also committed to selling certain prescription medicines directly to American patients through a Trump-branded website. In return, companies received tariff relief as part of the administration’s broader effort to negotiate lower drug prices.
At the center of Trump’s strategy is the most-favored-nation drug pricing model. The policy seeks to ensure that U.S. government healthcare programs do not pay substantially more for medicines than comparable developed countries.
The latest pharmaceutical agreements signal that lowering prescription drug costs remains a major healthcare priority for the Trump administration. If implemented broadly, the pricing model could increase pressure on drugmakers to reduce U.S. prices while potentially reshaping how medicines are priced across international markets.
